Isto Biologics
The Orthobiologics Pioneers

Historically, the treatment for bone and spine injuries incurred long recovery times for patients. Orthobiologics has been a game-changer in this regard by enabling rapid healing by leveraging cell regeneration via the use of various biologic solutions ranging from amniotic fluids to a patient’s aspirated bone marrow cells. Pioneering this innovative approach is Isto Biologics—a leading biologics and regenerative medicine company whose mantra is helping patients heal faster. “We do that by developing and providing novel orthobiologics solutions for our surgeons and their patients in the operating room,” says Don Brown, CEO of Isto Biologics. “Our cellular based solutions enable rapid bone healing and help broaden the surgical options for spine and orthopedic treatments.”

The patient’s own bone (autograft) has always been the gold standard because of its ability to deliver all three components required for bone growth: Osteoinductivity, osteoconductivity, and osteogenic cells. However, utilizing autograft has challenges including donor site morbidity and a limited quantity of harvest. As a result, surgeons often need products that can supplement or replace autograft while still providing all three osteo-components required for bone growth.

To this end, Isto Biologics offers InQu™, a line of cell-friendly, biosynthetic bone graft extenders that are offered in a moldable or flowable putty, a formable sheet that helps contain autograft, and as loose granules that can be used to extend autograft.

To complete the bone growth trifecta, Isto Biologics focuses on concentrating a patient’s native osteogenic cells and osteoinductive growth factors through their cellular concentration platform, Magellan®.

The Magellan® is an autologous concentration system that delivers concentrated platelets and cells at the point of care. The resulting cell concentrate can then be combined with autograft or allograft and delivered back to the patient, amplifying the patients’ own biology safely and quickly.

Our cellular based solutions enable rapid bone healing and help broaden the surgical options for spine and orthopedic treatments

Isto Biologics has recently expanded its’ bone growth portfolio with two new lines: Influx™, a line of advanced, pure-human, demineralized bone fiber (DBF) available in strips, loose fibers, or putty. The Influx™ line delivers a versatile osteoconductive and osteoinductive scaffold.

The second line is Influx™ SPARC, a cortical fiber, cell-based matrix that combines the Influx™ cortical fibers with osteoprogenitor cells and high concentrations of growth factors.

Brian Barnes, who serves as the company President, talks about the dual approach the company takes. “We were one of the first to focus on providing a range of options that position us as a one-stop biologics shop, while also being open to individual surgeon preferences so they can tailor-fit products to meet their specific surgical requirements.”

Nathan Taylor, VP of Sales & Marketing echoes that thought process. “We want to be very nimble to quickly pivot to meet a surgeon’s specific needs,” he says. “Our team works with hospitals and physician feedback so that we can quickly develop and improve our offerings to meet all our customer’s requirements.”

In several instances, the company has gone out of their way to create products that solve their client’s challenges with offerings such as Influx™ and the one-of-a-kind Lightning NeedleTM Bone Marrow Aspiration Cannula System, a single-use, disposable device that contains eight large, bevel-edged fenestrations allowing for gentle bone marrow aspiration.

With a keen focus on their mantra and the zeal to understand every pain-point of their clients, Isto Biologics will continue to look for novel orthobiologic solutions that fill the gaps in the industry while delivering the highest quality products. “We have enabled surgeries in 35 countries apart from the US and are planning to expand our footprint into more countries this year, including our launch in Japan,” concludes Brown.